- Home
- XXII vs HEPA Comparison
XXII vs HEPA Comparison
Compare XXII & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- HEPA
- Stock Information
- Founded
- XXII 1998
- HEPA 2013
- Country
- XXII United States
- HEPA United States
- Employees
- XXII N/A
- HEPA N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- HEPA Health Care
- Exchange
- XXII Nasdaq
- HEPA Nasdaq
- Market Cap
- XXII 4.0M
- HEPA 4.7M
- IPO Year
- XXII N/A
- HEPA N/A
- Fundamental
- Price
- XXII $0.09
- HEPA $0.68
- Analyst Decision
- XXII
- HEPA Hold
- Analyst Count
- XXII 0
- HEPA 1
- Target Price
- XXII N/A
- HEPA N/A
- AVG Volume (30 Days)
- XXII 9.6M
- HEPA 39.0K
- Earning Date
- XXII 11-12-2024
- HEPA 11-26-2024
- Dividend Yield
- XXII N/A
- HEPA N/A
- EPS Growth
- XXII N/A
- HEPA N/A
- EPS
- XXII N/A
- HEPA N/A
- Revenue
- XXII $9,918,000.00
- HEPA N/A
- Revenue This Year
- XXII $56.94
- HEPA N/A
- Revenue Next Year
- XXII $2.98
- HEPA N/A
- P/E Ratio
- XXII $0.03
- HEPA N/A
- Revenue Growth
- XXII N/A
- HEPA N/A
- 52 Week Low
- XXII $0.09
- HEPA $0.55
- 52 Week High
- XXII $5.28
- HEPA $4.47
- Technical
- Relative Strength Index (RSI)
- XXII 31.38
- HEPA 52.88
- Support Level
- XXII $0.09
- HEPA $0.60
- Resistance Level
- XXII $0.13
- HEPA $0.68
- Average True Range (ATR)
- XXII 0.01
- HEPA 0.05
- MACD
- XXII 0.01
- HEPA 0.00
- Stochastic Oscillator
- XXII 10.51
- HEPA 87.80
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.